BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the
"Company"), a medical technology company commercializing an
innovative signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals, today announced that it is installing a PURE EP™ System
for an evaluation at the HCA Healthcare-operated Medical City Heart
Hospital in Dallas, TX. This is the Company’s 17th installation and
its fifth in Texas, the state with some of the most extensive
clinical programs focused on arrhythmia care in the country.
Opened in 2019, Medical City Heart Hospital, a cardiovascular
department of Medical City Dallas Hospital, provides the most
comprehensive heart and vascular treatment in the
Southwest. As a part of Medical City Healthcare, the facility
offers highly specialized advanced cardiovascular care,
including leading-edge treatments and technology,
ground-breaking clinical trials, and seamless access to the entire
network of Medical City Healthcare hospitals and
specialists.
“Heart disease and stroke remain at the top of leading causes of
disability in Texas1, and we are committed to working with more
physicians in this state as they strive to reduce the societal
burden caused by heart disease. Medical City Heart provides
specialized care for all types of cardiac rhythm disorders, and we
are looking forward to contributing our technological and clinical
know-how in this new collaboration,” commented Kenneth L. Londoner,
Chairman, and CEO of BioSig Technologies, Inc.
To date, over 71 physicians have completed over 1600 patient
cases with the PURE EP™ System. The Company is in a focused
commercial launch of the PURE EP™ System in the Northeast, Texas,
and Florida. The technology is regularly used in some of Texas’s
highest-ranked hospitals, including St. David’s Medical Center,
Houston Methodist Hospital, and Medical City North Hills.
Clinical data acquired by the PURE EP™ System in a multi-center
study at Texas Cardiac Arrhythmia Institute at St. David’s Medical
Center, Mayo Clinic Jacksonville and Massachusetts General Hospital
was recently published in the Journal of Cardiovascular
Electrophysiology and is available electronically with open access
via the Wiley Online Library. Study results showed 93% consensus
across the blinded reviewers with a 75% overall improvement in
intracardiac signal quality and confidence in interpreting PURE EP™
signals over conventional sources.
About 2,300 Americans die from heart disease each day – an
average of one death every 38 seconds2. In 2016, 1.6 million Texas
adults reported that they had been diagnosed with heart disease or
stroke3. There were 336,462 hospitalizations of adult Texans
related to heart disease in 2016, at an age-adjusted rate of 124.0
per 10,000 adults4. The direct and indirect costs of heart disease
and stroke in the U.S. are estimated to be $329.7 billion, and the
cost is projected to increase to $749 billion by 20355.
About BioSig Technologies BioSig Technologies
is a medical technology company commercializing a proprietary
biomedical signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals (www.biosig.com).
The Company’s first product, PURE EP™ System is a computerized
system intended for acquiring, digitizing, amplifying, filtering,
measuring and calculating, displaying, recording, and storing
electrocardiographic and intracardiac signals for patients
undergoing electrophysiology (EP) procedures in an EP
laboratory.
Forward-looking Statements This press release
contains “forward-looking statements.” Such statements may be
preceded by the words “intends,” “may,” “will,” “plans,” “expects,”
“anticipates,” “projects,” “predicts,” “estimates,” “aims,”
“believes,” “hopes,” “potential” or similar words. Forward- looking
statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
associated with (i) the geographic, social and economic impact of
COVID-19 on our ability to conduct our business and raise capital
in the future when needed, (ii) our inability to manufacture our
products and product candidates on a commercial scale on our own,
or in collaboration with third parties; (iii) difficulties in
obtaining financing on commercially reasonable terms; (iv) changes
in the size and nature of our competition; (v) loss of one or more
key executives or scientists; and (vi) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
1 Prevalence of Heart Disease Among Adults, by Demographic
Characteristics, Risk Factors / Comorbid Conditions, and Place of
Residence, Texas 2018; Chronic Disease Epidemiology Branch, Texas
Department of State Health Services.
2 Heart disease and stroke statistics – 2018 update: a report
from the American Heart Association
3 Texas Behavioral Risk Factor Surveillance System Public Use
Data File, 2016, Center for Health Statistics, Texas Department of
State Health Services
4 Texas Hospital Inpatient Discharge Public Use Data, Texas
Health Care Information Collection, 2016, Center for Health
Statistics, Texas Department of State Health Services
5 Heart disease and stroke statistics – 2018 update: a report
from the American Heart Association
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
55 Greens Farms Road
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Jun 2024 to Jul 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Jul 2023 to Jul 2024